【摘要】 目的分析地西他滨治疗骨髓增生异常综合征(MDS)和急性髓系白血病(AML)的临床效果。方法将2010年1月~2015年12月纳入研究的MDS和AML患者共30例,采用马法兰联合强的松治疗,作为对照组;2016年1月~2017年12月共纳入研究对象30例作为观察组,均为MDS和AML患者,采用地西他滨治疗,分析两组的临床效果。结果观察组疾病控制20例(66.67%),总有效率66.67%(20/25),平均生存期为(10.89±1.89)个月。对照组疾病控制5例(16.67%),总有效率16.67%(5/30),平均生存期为(3.91±1.03)个月。两组疗效比较差异均有统计学意义(P<0.05)。对照组骨髓抑制伴发热5例,观察组发生20例,差异有统计学意义(P<0.05),其他不良反应发生率无显著差异(P>0.05)。结论地西他滨治疗骨髓增生异常综合征和急性髓系白血病的临床疗效明显,值得临床推广。更多还原

【Abstract】 Objective To analyze the clinical effects of decitabine in the treatment of myelodysplastic syndromes(MDS) and acute myeloid leukemia(AML). Methods A total of 30 patients with MDS and AML who were included from January 1, 2010 to December 30, 2015 were treated with the combination of melphalan and prednisone as a control group. From January 1, 2016 to November, 2017, A total of 30 subjects were included in the observation group as MDS and AML patients, treated with decitabine, and the clinical effects of the two groups were analyzed. Results The observation group had 20 cases(66.67%)of disease control, a total effective rate of 66.67%(20/25), and an average survival period of(10.89±1.89) months. Control group disease control in 5 cases(16.67%), the total effective rate was 16.67(5/30), and the average survival period was(3.91±1.03) months. In the control group, there were significant differences between 5 cases of bone marrow suppression with fever and 20 cases of observation group(P < 0.05), and there was no significant difference in other adverse reactions(P > 0.05). Conclusion Decitabine is effective in the treatment of myelodysplastic syndrome and acute myeloid leukemia. It is worthy of clinical promotion.更多还原